Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.22 USD | -0.19% | -0.15% | -11.67% |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.67% | 478M | |
+10.45% | 118B | |
+10.37% | 106B | |
-11.48% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.79% | 15.97B | |
+7.49% | 14.03B | |
+17.41% | 11.67B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma : Oppenheimer Adjusts UroGen Pharma PT to $34 From $40, Maintains Outperform Rating